1.Bulletin of the Chemical Society of Japan, Volume 26, Pages 119-122, Journal, 1953
2.Dalton Transactions 2017,vol. 46, # 5, p. 1510 - 1519
3.Design and evaluation of ophthalmic pharmaceutical products. In Banker GS, Rhodes CT, eds. Modern Pharmaceutics, 4th edn. New York Marcel Dekker, 2002 415-478
4.Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer
5.Journal of Photochemistry and Photobiology, B Biology, Volume 97, Issue 1, Pages 18-21, Journal, 2009
6.Journal of Photochemistry and Photobiology, B Biology, Volume 115, Pages 51-57, Journal; Online Computer File, 2012
7.Nair AD, Lach JL. The kinetics of degradation of chlorobutanol. J Am Pharm Assoc (Sci) 1959; 48 390-395.
8.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
9.Plasma renin activity-guided strategy for the management of hypertension.
10.Stability of chlorobutanol in aqueous solutions Journal of the American Pharmaceutical Association (1961), Volume 6, Issue 7, July 1966, Pages 372-373
11.Talanta, Volume 146, Pages 732-736, Journal; Online Computer File, 2016
[更多]
渝公网安备 50010802001068号
